Kite, a Gilead Company, today announced it has received approval to implement a variation to the Yescarta® (axicabtagene ciloleucel) Marketing Authorization from the European Medicine Agency (EMA) for end-to-end manufacturing. The new European facility sits next to one of Europe’s largest airports, Amsterdam Airport Schiphol. This central location, with its transport links to the region, will reduce the delivery time to and from treatment centers. The facility has the capacity to produce therapy for up to 4,000 patients per year.